Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

NeOnc's glioma readout shows two different results, depending on the response criteria used

The Nasdaq-listed company says its intranasal NEO100 succeeded in a 24-patient recurrent glioma study, but the protocol's own scoring method gives a far weaker figure.

17 Nov 2026 · Neonc Technologies Holdings, Inc. NTHI · Company news

NeOnc Technologies (NASDAQ: NTHI) is presenting early data on NEO100 as a positive result, but the commercial weight of the claim depends on which tumour-response yardstick is used. The company's slide material reports that the Phase 2a study cleared its main goal. The protocol-specified scoring method points to a much more modest outcome.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Neonc Technologies Holdings, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →